Research Interest

Molecular pathophysiological mechanisms including genetics and epigenetics, biomarkers, both biochemical (chiefly CSF) and imaging and experimental therapies (clinical trials) in Parkinson’s disease and other movement disorders.

Technologies & Methods

• Disease/disorder characterisation: Endophenotypification studies
• Assessment of new treatments: Clinical trials, non-dopa agents
• Methods for diagnostic: Cerebrospinal fluid (CSF) and imaging biomarkers
• Clinical data: Collaborative clinical registries
• Development of new tools / technologies / computational methods: Implement new CSF (RTQuIC) and PET (foreseeably in the future tau and eventually alpha-synuclein) markers

Active Projects

• • Plataforma Traslacional para la AMS: Descubriendo mecanismos patológicos y nuevas dianas terapéuticas: PTra- ADPT. Instituto de Salud Carlos III. AC21_2/00018. Yaroslau Compta.

• • Psp registry: clinical cohort study with biomarkers study of prediagnostic cases and health education program in established disease. Fundació La Marató de TV3. 202009-10. Yaroslau Compta.

• • 3 Confidential agreements.

Selected Publications

• • Cámara, A., Compta, Y., Pérez-Soriano, A., Montagut, N., Baixauli, M., Maragall, L., Ludeña, E., Lopez de Los Reyes, J. C., Peri-Cusi, L., Fernández, N., Villote, S., Ahuir, M., Grau, A., Caballol, N., Buongiorno, M., Pont-Sunyer, C., Puente, V., Giraldo, D. M., de Fabregues, O., Garrido, A., … Martí, M. J. (2021). Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program. Parkinsonism & Related Disorders, 86, 78–80. https://doi.org/10.1016/j.parkreldis.2021.03.021

• • Esteller, D., Modreanu, R., Cerquera-Cleves, S. C., Sánchez-Gómez, A., Fernández, M., Cámara, A., & Compta, Y. (2021). Cross-sectional associations of cerebrospinal α-synuclein, tau and amyloid-β with dyskinesias, motor fluctuations, non-motor symptoms in a cohort of Parkinson’s disease patients. Journal of the Neurological Sciences, 430, 120033. https://doi.org/10.1016/j.jns.2021.120033

• • Guasp, M., Molina-Porcel, L., Painous, C., Caballol, N., Camara, A., Perez-Soriano, A., Sánchez-Gómez, A., Garrido, A., Muñoz, E., Marti, M. J., Valldeoriola, F., Grau, O., Gelpí, E., Respondek, G., Höglinger, G. H., & Compta, Y. (2021). Association of PSP phenotypes with survival: A brain-bank study. Parkinsonism & Related Disorders, 84, 77–81. https://doi.org/10.1016/j.parkreldis.2021.01.015

• • Inguanzo, A., Segura, B., Sala-Llonch, R., Monte-Rubio, G., Abos, A., Campabadal, A., Uribe, C., Baggio, H. C., Marti, M. J., Valldeoriola, F., Compta, Y., Bargallo, N., & Junque, C. (2021). Impaired Structural Connectivity in Parkinson’s Disease Patients with Mild Cognitive Impairment: A Study Based on Probabilistic Tractography. Brain Connectivity, 11(5), 380–392. https://doi.org/10.1089/brain.2020.0939

• • Oltra, J., Campabadal, A., Segura, B., Uribe, C., Marti, M. J., Compta, Y., Valldeoriola, F., Bargallo, N., Iranzo, A., & Junque, C. (2021). Disrupted functional connectivity in PD with probable RBD and its cognitive correlates. Scientific Reports, 11(1), 24351. https://doi.org/10.1038/s41598-021-03751-5

• • Sánchez-Gómez, A., Compta, Y., & Martí, M. J. (2021). Insulinreleasing or insulin-sensitizing drugs in Parkinson’s disease? Choosing a pathway. Parkinsonism & Related Disorders, 93, 109–110. https://doi.org/10.1016/j.parkreldis.2021.10.017

• • Sánchez-Gómez, A., Díaz, Y., Duarte-Salles, T., Compta, Y., & Martí, M. J. (2021). Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: A population-based cohort study. Parkinsonism & Related Disorders, 89, 22–27. https://doi.org/10.1016/j.parkreldis.2021.06.002